Recent News

  • Biologic Dosing and Obesity

    Jiha Lee, MD
    Puzzle pieces

    A 46-year-old with psoriatic arthritis and a BMI of 38 still has active disease on adalimumab (Humira) 40 mg every other week. What do you do? Switch class, optimize methotrexate, or ask whether the dose itself is too low?

    Read Article
Dr. John Cush Tweet
@RheumNow
RheumNow’s expanded coverage of the #ACR26 meeting is sponsored by Eli Lilly and Company. All content is independently selected by RheumNow and its faculty.
Dr. John Cush Tweet
@RheumNow
RheumNow’s expanded coverage of #ACR26 Annual Meeting is sponsored by Beeline Medicines, Boehringer Ingelheim, Bristol Myers Squibb, and Tonix. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush Tweet
@RheumNow
ACR 2026 – Day 1 Report ACR Convergence was off to a big start with the year in review, posters and plenary sessions. Here are a few of our favorite presentations from today's Plenary I session at ACR Convergence. 2/5 plenary abstracts focused on weight loss, one on artificial https://t.co/d1u0nElhov
Antoni Chan MD (Prof) Tweet
@synovialjoints
Late breaking, ICONIC PsA 1: icotrokinra, a once daily oral peptide targeting the IL23 receptor, in biologic naive PsA. Week 16 ACR20 58% vs 41% with placebo; ACR50 29% vs 16%; clear or almost clear skin 57% vs 14%. Key finding: the primary endpoint was met, with ACR20 69% and
Mrinalini Dey Tweet
@DrMiniDey
CDAI remission does not describe every symptom. In a 787-patient RA study, those in remission still had meaningful pain interference (19%), fatigue (20%) and impaired function (23%). PROMIS scores show symptoms that composite score missed. #2874 @Rheumnow #ACR26
Antoni Chan MD (Prof) Tweet
@synovialjoints
In 1,602 patients in the Brazilian Registry of Spondyloarthritis, moving from ASAS 2009 to ASAS SPARTAN 2025 removed 74 axSpA patients and added none. Only 39.2% of those removed had sacroiliitis on imaging, and they more often had psoriasis, IBD, female sex and later symptom
Akhil Sood MD, MS Tweet
@AkhilSoodMD
How well does PREVENT predict HF and total CVD in lupus? Abst 2861 found: - Moderate discrimination for both outcomes (C=0.70 each) - Sensitivity of 53% for HF and 67% for total CVD - PREVENT underestimated both risks across deciles #ACR26 @RheumNow
Brian Jaros, MD Tweet
@Dr_Brian_MD
Secukinumab works regardless of erosive burden in PsA Post-Hoc analysis of FUTURE-5: ACR20 when stratified by baseline erosion score nearly identical in TNF-naive pt ACR20 in TNF-exposed pt numerically higher in those w/ greater erosive burden @rheumnow #ACR26 Abst2285
Akhil Sood MD, MS Tweet
@AkhilSoodMD
Can adverse pregnancy outcomes predict SLE or RA? Abstract 2860 found: - Future SLE assoc. w/ hx of preeclampsia (aOR 1.89), emergency c-section (aOR 1.90), and short gestational duration (aOR 0.93) - Future RA assoc w high pre-pregnancy BMI (aOR 1.19) @RheumNow #ACR26
Brian Jaros, MD Tweet
@Dr_Brian_MD
Which patient with ICI joint disease will have persistent disease? Risk factors include: - tenosynovitis on US/MRI - elevated CRP - baseline GC use - age <65 - peripheral inflam arthritis pattern @RheumNow #ACR26 Abst2806

Video

Podcasts

  • ACR 2026 Daily Podcasts - Day2c
  • ACR 2026 Daily Podcasts - Day2b
  • ACR 2026 Daily Podcasts - Day2a
  • ACR 2026 RheumNow Day 2 Recap
Ask Cush Anything

Submit your Rheumatology question or case here

Therapeutic Updates

Individualized PsA Treatment With an IL-23i or a JAKi

Sponsored by AbbVie Medical Affairs + Health Impact
AbbVie November RX Update
In Part 2 of our PsA management series, Saakshi Khattri, MD, and Lindsay Tom, PA-C, discuss tailoring treatment for patients with multidomain PsA and how IL-23i and JAKi data guide their decisions
Read Post
×